These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34589084)

  • 1. Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer.
    Huang F; Pan N; Wei Y; Zhao J; Aldarouish M; Wang X; Sun X; Wen Z; Chen Y; Wang L
    Front Immunol; 2021; 12():707298. PubMed ID: 34589084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells.
    Huang F; Zhao J; Wei Y; Wen Z; Zhang Y; Wang X; Shen Y; Wang LX; Pan N
    Int J Nanomedicine; 2020; 15():1021-1035. PubMed ID: 32103954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.
    Chandra D; Quispe-Tintaya W; Jahangir A; Asafu-Adjei D; Ramos I; Sintim HO; Zhou J; Hayakawa Y; Karaolis DK; Gravekamp C
    Cancer Immunol Res; 2014 Sep; 2(9):901-10. PubMed ID: 24913717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.
    Aldarouish M; Wang H; Zhou M; Hu HM; Wang LX
    J Exp Clin Cancer Res; 2015 Apr; 34(1):34. PubMed ID: 25886865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy.
    Luo M; Liu Z; Zhang X; Han C; Samandi LZ; Dong C; Sumer BD; Lea J; Fu YX; Gao J
    J Control Release; 2019 Apr; 300():154-160. PubMed ID: 30844475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
    Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
    Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
    Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
    Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.
    Yin M; Hu J; Yuan Z; Luo G; Yao J; Wang R; Liu D; Cao B; Wu W; Hu Z
    Cell Cycle; 2022 Apr; 21(8):767-779. PubMed ID: 35130108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma.
    Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
    Cancer Immunol Res; 2018 Nov; 6(11):1417-1425. PubMed ID: 30143536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
    Fu J; Kanne DB; Leong M; Glickman LH; McWhirter SM; Lemmens E; Mechette K; Leong JJ; Lauer P; Liu W; Sivick KE; Zeng Q; Soares KC; Zheng L; Portnoy DA; Woodward JJ; Pardoll DM; Dubensky TW; Kim Y
    Sci Transl Med; 2015 Apr; 7(283):283ra52. PubMed ID: 25877890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.
    Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C
    Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vx3-Functionalized Alumina Nanoparticles Assisted Enrichment of Ubiquitinated Proteins from Cancer Cells for Enhanced Cancer Immunotherapy.
    Zhao J; Pan N; Huang F; Aldarouish M; Wen Z; Gao R; Zhang Y; Hu HM; Shen Y; Wang LX
    Bioconjug Chem; 2018 Mar; 29(3):786-794. PubMed ID: 29382195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
    Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
    J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2.
    Yan HX; Cheng P; Wei HY; Shen GB; Fu LX; Ni J; Wu Y; Wei YQ
    Oncol Rep; 2013 Apr; 29(4):1510-6. PubMed ID: 23404510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.